A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Public ClinicalTrials.gov record NCT03690388. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior vascular endothelial growth factor receptor (VEGFR)-Targeted therapy.
Study identification
- NCT ID
- NCT03690388
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 187 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 5, 2018 (Actual)
- Primary completion
- Aug 19, 2020 (Actual)
- Completion
- Jul 31, 2027 (Estimated)
- Last update posted
- Oct 20, 2026
2018 – 2027
United States locations
- U.S. sites
- 31
- U.S. states
- 19
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Exelixis Clinical Site #2 | Newport Beach | California | 92658 | — |
| Exelixis Clinical Site #98 | Sacramento | California | 95817 | — |
| Exelixis Clinical Site #69 | San Francisco | California | 94115 | — |
| Exelixis Clinical Site #10 | Stanford | California | 94305 | — |
| Exelixis Clinical Site #3 | Torrance | California | 90502 | — |
| Exelixis Clinical Site #9 | Aurora | Colorado | 80045 | — |
| Exelixis Clinical Site #21 | New Haven | Connecticut | 06510 | — |
| Exelixis Clinical Site #4 | Washington D.C. | District of Columbia | 20010 | — |
| Exelixis Clinical Site #94 | Miami | Florida | 33136 | — |
| Exelixis Clinical Site #93 | Orlando | Florida | 32804 | — |
| Exelixis Clinical Site #6 | Tampa | Florida | 33612 | — |
| Exelixis Clinical Site #164 | Chicago | Illinois | 60637 | — |
| Exelixis Clinical Site #54 | Lexington | Kentucky | 40536 | — |
| Exelixis Clinical Site #153 | Boston | Massachusetts | 02114 | — |
| Exelixis Clinical Site #80 | Ann Arbor | Michigan | 48109 | — |
| Exelixis Clinical Site #78 | Detroit | Michigan | 48201 | — |
| Exelixis Clinical Site #22 | Detroit | Michigan | 48202 | — |
| Exelixis Clinical Site #63 | Columbia | Missouri | 65212 | — |
| Exelixis Clinical Site #42 | St Louis | Missouri | 63110 | — |
| Exelixis Clinical Site #11 | Omaha | Nebraska | 68114 | — |
| Exelixis Clinical Site #118 | Morristown | New Jersey | 07962 | — |
| Exelixis Clinical Site #76 | Charlotte | North Carolina | 28204 | — |
| Exelixis Clinical Site #19 | Durham | North Carolina | 27710 | — |
| Exelixis Clinical Site #7 | Cincinnati | Ohio | 45219 | — |
| Exelixis Clinical Site #5 | Bethlehem | Pennsylvania | 18015 | — |
| Exelixis Clinical Site #1 | Philadelphia | Pennsylvania | 19104 | — |
| Exelixis Clinical Site #75 | Pittsburgh | Pennsylvania | 15232 | — |
| Exelixis Clinical Site #134 | Charleston | South Carolina | 29425 | — |
| Exelixis Clinical Site #68 | Nashville | Tennessee | 37232 | — |
| Exelixis Clinical Site #8 | Houston | Texas | 77030 | — |
| Exelixis Clinical Site #113 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 133 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03690388, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 20, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03690388 live on ClinicalTrials.gov.